alexa RNAi Functional Genome Screens Identifies Novel Breast Cancer Drug Targets, Combination Therapies, And Potential Patient Selection Biomarkers
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Attila Seyhan
Accepted Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.010
Abstract
We conducted a genome-scale RNAi screens using pooled-lentiviral approach to identify synthetic lethal or enhancer genes that interact with neratinib in a human breast cancer cell line (SKBR-3). Our study identified a diverse set of genes and mechanisms whose perturbation by RNAi selectively impaired or enhanced the viability of cancer cells in the presence of subeffective concentrations of neratinib. Examining the changes of these genes and their protein products also led to a rationale for clinically relevant drug combination treatments. Treatment of cells with either paclitaxel or cytarabine in combination with neratinib resulted in a strong antiproliferative effect. The identification of novel targets and pathways to neratinib could lead to the development of novel selective therapies and combination therapies that overcome therapeutic resistance to neratinib and other ErbB2-targeted therapies. Notably, our findings support a paclitaxel and neratinib phase III clinical trial in breast cancer patients. In addition, we performed an RNAi screen to identify genes involved in resistance to lethal concentrations of neratinib under a long term selective pressure. The screen uncovered a set of novel genes whose silencing by RNAi caused long term chemoresistance to lethal concentrations of neratinib. The identification of novel mediators of cellular resistance to neratinib could lead to the identification of new or neoadjuvant drug targets. Additionally, these resistant genes if confirmed in patient samples can be used as patient or treatment selection biomarkers to select individuals who will most likely benefit from neratinib and other anti-ErbB therapies.
Biography
Attila Seyhan is a Faculty at the Translational Research Institute (TRI) for Metabolism and Diabetes and a scientific advisor to Biomarker Discovery and Development Unit of TRI. He is also an Adjunct Professor at the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, FL and holds a position as a Research Affiliate in the Department of Chemical Engineering, Massachusetts Institute of Technology (MIT). Previously, he was a Senior Translational Medicine Leader in Inflammation and Immunology and Clinical R&D at Pfizer and was the Head of Functional Genomics at Wyeth Inc. He earned his Ph.D. in Biological Sciences from Michigan Technological University (MTU).
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords